InvestorsHub Logo
Followers 0
Posts 74
Boards Moderated 0
Alias Born 03/18/2018

Re: None

Wednesday, 08/08/2018 8:51:17 AM

Wednesday, August 08, 2018 8:51:17 AM

Post# of 18784
Strongbridge Biopharma (licensee of Macrilen in the USA and Canada) reported Second Quarter 2018 earnings this morning. Strongbridge CEO Matthew Pauls said today that "....we are particularly excited about the launch of MACRILEN, which providrs Strongbridge with an efficient, synergistic, presence in the rare endocrine community ahead of the potential regulatory approval of RECORLEV. Early launch indicators are encouraging, signaling pent-up demand for this novel solution to diagnose adult growth hormone deficiency (AGHD), a serious, rare, under-diagnosed disease." https://markets.businessinsider.com/news/stocks/strongbridge-biopharma-plc-reports-second-quarter-2018-financial-results-and-provides-corporate-update-1027441849
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AEZS News